GlassScriptPhysician profile
Murthy Vs Mangipudi
NPI 1558350603
$3,769.13
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $824 · 2021: $887 · 2022: $860 · 2023: $380 · 2024: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $616.63 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $546.54 | 2021-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $533.36 | 2020-2024 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $527.78 | 2019-2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $379.62 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $203.41 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $201.94 | 2019-2023 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $180.51 | 2019-2022 | |
| Abbvie INC. | $130.70 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $122.72 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $76.14 | 2019-2022 | |
| Corium, LLC | $57.60 | 2021-2023 | Azstarys |
| Eisai INC. | $52.83 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $47.47 | 2022 | |
| Neos Therapeutics, LP | $31.73 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.52 | 2020-2023 | |
| Allergan, INC. | $28.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murthy Mangipudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.